Kisspeptin dosage: Frequently asked questions

Kisspeptin-10, kisspeptin-13, and kisspeptin-54 are not equipotent on a molar basis and cannot be directly compared using nmol/kg dosing. Kisspeptin-10 represents the minimal active fragment (amino acids 45–54 of the full kisspeptin-54 sequence) and is the most commonly used in research. Kisspeptin-54 has lower receptor binding affinity per molecule and is cleared more slowly. When comparing studies, note which fragment was used and refer to dose-response curves published for each fragment in the same species and administration route. If replicating a kisspeptin-54 protocol with kisspeptin-10, start at approximately 50% of the published dose and titrate based on response, as kisspeptin-10 typically shows higher receptor occupancy per nmol administered.

Precipitation indicates either incorrect reconstitution solvent, pH incompatibility, or peptide degradation prior to reconstitution. Kisspeptin-10 should be reconstituted in bacteriostatic water or sterile saline. Never use plain water, which lacks preservatives and has variable pH. If precipitation occurs, gently swirl (do not shake or vortex, as mechanical stress denatures peptides) and allow 2–3 minutes for dissolution. If precipitation persists, the peptide is likely denatured and unusable. Discard and source replacement peptide from a verified supplier with documented storage and handling throughout cold chain.

Convert using molecular weight and the relationship 1 nmol = molecular weight in nanograms. For kisspeptin-10 (MW 1302 g/mol), 1 nmol = 1302 ng = 1.302 µg. If the protocol calls for 100 µg/kg and your subject weighs 70kg, the total dose is 7000 µg = 7 mg. To express this in nmol: (7000 µg ÷ 1.302 µg/nmol) = 5376 nmol, or 76.8 nmol/kg. Always verify which unit system your source protocol uses. Mixing mass-based and molar dosing without conversion is the most common calculation error in peptide research.

Calculate total peptide required for the entire study duration first, then reconstitute in a volume that allows precise measurement of each dose while staying within the 14-day stability window for refrigerated storage. For example, if your protocol requires 0.1mg per injection and you'll administer 10 doses over 10 days, you need 1mg total. Reconstitute a 1mg vial in 1mL, yielding 1mg/mL, so each dose is 0.1mL. Store at 2–8°C and draw fresh for each injection using aseptic technique. Never leave the vial at room temperature between uses, as this accelerates degradation.

Female subjects in early follicular phase (days 2–5 of the menstrual cycle) show reduced kisspeptin sensitivity compared to late follicular phase due to lower circulating estradiol, which normally upregulates GPR54 receptor density on GnRH neurons. You may need to increase the dose by 20–30% to achieve equivalent LH stimulation compared to late follicular subjects. Conversely, administering the standard 0.3–1.0 nmol/kg dose during the preovulatory LH surge window (cycle day 12–14) can produce exaggerated LH responses exceeding 20 IU/L. This is exploited in fertility research protocols aiming to trigger ovulation.

Do not attempt direct unit conversion. The routes are not pharmacokinetically equivalent. Instead, reference published subcutaneous trials for the specific peptide variant you are using. For kisspeptin-10, start at 6.4 nmol/kg subcutaneous and titrate based on measured LH response rather than extrapolating from IV infusion rates. The absorption kinetics are fundamentally different: IV delivers 100% bioavailability instantaneously, while subcutaneous bioavailability for peptides ranges 40–70% with peak plasma levels occurring 30–90 minutes post-injection. A 1.0 nmol/kg/hour IV infusion over two hours (120 nmol/kg total delivered) does not equal a 120 nmol/kg subcutaneous bolus. The latter would produce unpredictable peak levels and potential receptor oversaturation.

Increase the dose incrementally from 1.0 nmol/kg to 2.0–3.0 nmol/kg and measure LH at 90, 120, and 150 minutes post-injection to capture delayed absorption kinetics. Subcutaneous bioavailability varies by injection site (abdominal subcutaneous tissue shows faster absorption than thigh), so standardising site and depth improves consistency. If LH response remains below 2× baseline at 3.0 nmol/kg subcutaneous, the formulation may be degraded or improperly reconstituted. Peptides stored above 4°C or reconstituted with non-bacteriostatic water lose activity within 48–72 hours.

Add bacteriostatic water slowly down the vial wall. Never inject directly onto the peptide cake. Vigorous shaking denatures the peptide structure irreversibly, rendering the solution inactive even if it appears clear. Reconstituted kisspeptin should be gently swirled until fully dissolved, stored at 2–8°C, and used within 14 days. A temperature excursion above 8°C for more than 2 hours causes aggregation that neither visual inspection nor standard potency testing at bench level can detect. The peptide looks fine but GPR54 binding affinity drops below therapeutic threshold.

GPR54 receptor downregulation occurs when kisspeptin occupancy is sustained without recovery intervals. Implement a 2-day washout period (no dosing), then resume at 75% of the original dose. If the study design requires continuous dosing, switching to every-other-day administration maintains receptor sensitivity longer than daily protocols. Research from the University of Cambridge demonstrated that 48-hour dosing intervals preserved LH response across 4 weeks, while daily dosing showed 40% attenuation by week 2.

Use pulsatile IV infusion at 0.15–0.25 nmol/kg every 75 minutes rather than continuous infusion. A programmable syringe pump delivers precise timed boluses that mimic endogenous GnRH pulsatility, maintaining LH between 1.5–2.5× baseline without triggering receptor desensitisation. Continuous infusion will suppress LH by hour 6–8 regardless of dose. The pituitary gonadotropes internalise GnRH receptors under sustained stimulation, shutting down LH synthesis. Pulsatile protocols administered for up to 24 hours in clinical trials have maintained stable LH output without tachyphylaxis.

Subcutaneous administration at typical IV doses (1.0mcg/kg) often fails to reach therapeutic plasma concentration due to low bioavailability. If initial SC dosing shows negligible LH elevation, increase to 3.0–4.0mcg/kg and reassess response at 60 minutes post-injection. Injection site matters: abdominal subcutaneous tissue shows higher absorption than thigh or deltoid due to increased blood flow. Alternatively, switching to intravenous administration eliminates bioavailability variability entirely and confirms peptide potency.

This indicates receptor desensitisation. KISS1R internalisation in response to sustained high-dose exposure. Reduce dose by 30–50% or extend the interval between administrations to allow receptor re-expression. In IV protocols, this means stepping down from 1.0 to 0.3 nmol/kg/hour; in subcutaneous protocols, switching from daily 12.8 nmol/kg to every-other-day 6.4 nmol/kg. The hypothalamic-pituitary axis requires 24–48 hours to restore baseline receptor density after supraphysiological kisspeptin exposure. Continuing at the original dose when response has attenuated wastes peptide and delays research timelines. The system is offline, not unresponsive.

Recalculate effective dose to account for reduced active content. If purity is 92%, a nominal 10 mg vial contains 9.2 mg active peptide. Your reconstitution calculations must reflect this or you will underdose by 8%. More critically, assess what constitutes the remaining 8%: synthesis byproducts (truncated sequences, desamido variants) or contamination (salts, solvents, microbial endotoxins). Peptides below 90% purity should not be used in any protocol where precise dose-response relationships matter. The impurities create noise in LH measurements that cannot be controlled for. High-purity kisspeptin for research-grade work means ≥98% by HPLC, preferably verified by mass spectrometry showing a single dominant peak at the expected molecular weight.

Kisspeptin continuous infusion targets a different mechanism than dopamine agonists or pulsatile GnRH therapy. It acts upstream of GnRH neurons rather than replacing GnRH directly. The Massachusetts General Hospital protocol uses 0.01 nmol/kg/hour for the first four weeks, escalating to 0.04 nmol/kg/hour if LH pulsatility doesn't resume. Response typically occurs within 6–8 weeks if the HPG axis is reversibly suppressed (functional HA from energy deficit or stress) but fails in cases of organic hypothalamic damage. Concurrent normalisation of energy availability. Minimum 30 kcal/kg fat-free mass daily. Is non-negotiable; kisspeptin cannot override active metabolic suppression.

Request a baseline assessment of your OHSS risk factors. Specifically, antral follicle count above 20, estradiol levels exceeding 3,000 pg/mL, and PCOS diagnosis. Kisspeptin at 6.4 nmol/kg IV produces LH surge kinetics nearly identical to 10,000 IU hCG but with transient corpus luteum stimulation that resolves within 48–72 hours. The 2021 Cochrane meta-analysis found live birth rates of 26.3% with kisspeptin trigger vs 27.1% with hCG (not statistically different), but severe OHSS occurred in 0.6% of kisspeptin cycles vs 1.8% of hCG cycles. If you're a high responder, the OHSS risk reduction alone justifies the switch.

First confirm administration timing and route. IV bolus must be given as a push over 30–60 seconds, not diluted in saline bags. Subtherapeutic response at 1.6 nmol/kg is common in women with BMI above 28 or insulin resistance; the standard escalation is 3.2 nmol/kg, then 6.4 nmol/kg if needed. Draw LH at baseline, 60 minutes, and 4 hours post-injection to capture peak timing. If LH fails to rise above 10 IU/L at any timepoint on 6.4 nmol/kg, suspect KISS1R polymorphism (rare but documented) or pituitary hyporesponsiveness requiring further endocrine workup.